Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Status:
Active, not recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The investigators will perform a double blind, placebo controlled clinical trial with Xolair
(omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut
allergy. The investigators will determine if pretreatment with anti-IgE mAb
(Xolair/omalizumab) can greatly reduce allergic reactions and allow for faster and safer
desensitization.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital
Collaborators:
Ann & Robert H Lurie Children's Hospital of Chicago Children's Hospital of Philadelphia Stanford University